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The low oxygen levels that exist at high altitudes are often a 
difficulty for those that live, work, and travel to these extreme 
environments. Most people successfully adjust to the low 
partial pressure of oxygen, while those who do not use proper 
acclimatization or ascent profiles can develop acute mountain 
sickness (AMS). AMS occurs when individuals go too high in 
altitude too quickly. The pathophysiology behind AMS remains 
unknown, however, AMS is associated with hypoxemia (low 
blood oxygen) which everyone gets when going to high altitude 
(Loeppky et. al., 2008). A patent foramen ovale (PFO) is a 
passage for blood between the left and right atria. It allows 
deoxygenated blood to pass from the right atrium to the left 
atrium directly without going through pulmonary circulation to 
be oxygenated. Overall, this decreases the amount of oxygen 
in the blood. Therefore, it contributes to hypoxemia which can 
lead to increased incidence of AMS. Previous studies have 
found that the prevalence of AMS in subjects with PFO is much 
greater than the prevalence in those without a PFO (Elliott, 
2015; West, 2019). AMS is reported to be associated with 
systemic inflammation as measured by elevated cytokines 
such as interleukins (Wang, 2018). Preliminary data from our 
lab suggests that subjects with PFO (PFO+) have elevated 
levels of systemic inflammation which decreases after PFO 
closure. It was hypothesized that PFO+ subjects would have a 
higher level of systemic inflammation at baseline compared to 
subjects without PFO (PFO-). Upon exposure to a simulated 
altitude of 15600 feet, inflammation will increase in both groups 
but will be highest in the PFO+ group which will explain the 
increased susceptibility to AMS.
• 34 subjects (17 female)
• Saline contrast echocardiography to determine PFO presence
• UO Evonuk environmental chamber with 11.5% oxygen 
simulated ~15,600 ft 
• AMS scores & plasma samples collected before & at 10 hours 
in the chamber
• AMS scores assessed using the Lake Louise Questionnaire 
(LLQ)
• A subject with an LLQ score ≥ 3 plus a headache was 
characterized as AMS+
• Plasma samples were stored at -80°C in a freezer
• Plasma samples were assayed using a 13-Plex Bead Based 
Assay Kit
• Inflammatory markers include: IL-1β, INF-ɑ2, IFN-γ, TNF-ɑ, 
MCP-1, IL-6, IL-8, IL-10, IL-12p70, IL-17A, IL-18, IL-23, and IL-
33
• Beads were divided by size & internal fluorescence intensity to 
determine the quantity the cytokine concentration in each 
sample using flow cytometry.
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• Inflammation increased with exposure to hypoxia
• PFO+ group had the smallest increases in inflammation
• AMS+ group had the smallest increases in inflammation
• IFN-ɑ2 was significantly greater in the PFO+ group and may provide biomarkers 
for determining AMS susceptibility
• IL-12p70 was significantly greater in the AMS- group and may prevent AMS
• We conclude that inflammation induced by hypoxia may be beneficial and 
protective in those with low baseline levels of inflammation, thereby reducing 
AMS susceptibility
• We conclude that those individuals with chronically elevated baseline levels of 
inflammation have a blunted change in hypoxia-induced inflammation and 
therefore increased AMS susceptibility
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Figure 1. Inflammatory cytokines increase after 10 hours of hypoxia compared to 
baseline. Paired t-test. *p<0.05 
Figure 2. AMS+ subjects have a smaller increase in inflammation upon exposure to 
hypoxia than AMS- subjects. Two-way repeated measures ANOVA with Sidak post-hoc 
correction comparing the pre and 10-hour time points in AMS- and AMS+ participants. *p<0.05
Figure 3. PFO+ subjects had a lower change in IL-1β, TNF-ɑ, IL-6, IL-8, IL-18, IL-23, IL-33 
compared to PFO- subjects. Two-way repeated measures ANOVA with Sidak post-hoc correction 
comparing the pre and 10-hour time points in AMS- and AMS+ participants. *p<0.05
Figure 4. IFN-ɑ2 levels before and after hypoxia between PFO- and PFO+ subjects and IL-12p70 
levels before and after hypoxia between AMS- and AMS+ subjects. PFO+ subjects had significantly 
higher IFN-ɑ2 levels than PFO- subjects and IFN-ɑ2 was significantly increased after 10 hours of hypoxia 
in PFO+ subjects. AMS- subjects have significantly higher IL-12p70 levels than AMS+ subjects and IL-
12p70 was significantly increased after 10 hours of hypoxia in AMS- subjects. Two-way repeated 
measures ANOVA with Sidak post-hoc correction comparing the pre and 10-hour time points in AMS- and 
AMS+ participants. *p<0.05
